-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the GLOBOCAN database, the number of newly diagnosed breast cancer patients soared from 1.
According to the GLOBOCAN database, the number of newly diagnosed breast cancer patients soared from 1.
The incidence of BM in patients with metastatic breast cancer (mBC) is between 10-16% , and the incidence of BM in HER2+ patients may double to 22-36%
Nelatinib is an irreversible pan-HER tyrosine kinase inhibitor, showing systemic efficacy and intracranial activity in different stages of HER2+ breast cancer
Nelatinib is an irreversible pan-HER tyrosine kinase inhibitor, showing systemic efficacy and intracranial activity in different stages of HER2+ breast cancer
Between May 2013 and July 2017, the NALA study included 621 patients from 28 countries
Between May 2013 and July 2017, the NALA study included 621 patients from 28 countries
Among Asian mBC patients, the median PFS of the N+C group was longer than that of the L+C group [7.
Among Asian mBC patients, the median PFS of the N+C group was longer than that of the L+C group [7.
Among 202 Asian patients, 16 patients (15.
Among 202 Asian patients, 16 patients (15.
Among patients with measurable disease at baseline (n = 165), the ORR of the n+C group was 40.
Among patients with measurable disease at baseline (n = 165), the ORR of the n+C group was 40.
The median treatment time for neratinib and lapatinib were 6.
The median treatment time for neratinib and lapatinib were 6.
The incidence of TEAE leading to hospitalization and discontinuation of treatment was similar in the two groups of patients
In the Asian subgroup, TATE reported the most diarrhea, palmoplantar erythema dysperesthesia syndrome (PPE), and vomiting (Table 3)
.
Compared with lapatinib, the frequency of grade 3 diarrhea in patients treated with palmoplantar erythema syndrome is higher (25.
0% vs 6.
1%), and it is concentrated in the first cycle
.
There were 4 cases (3.
8%) and 1 case (1.
0%) in the N+C group
and 1 case (1.
0%) in the N+C group, respectively, due to diarrhea, and 1 case in the N+C group resulted in permanent treatment interruption .
Cardiac adverse events were rare in both groups.
Each group reported 1 case of pericardial effusion, 1 case of angina in the N+C group, and 1 case of acute myocardial infarction in the L+C group
.
Myocardial infarction
In summary, the results of the subgroup analysis of the study showed that the efficacy characteristics of Asian patients with HER2-positive advanced breast cancer who had failed two or more HER2-targeted therapies were consistent with the efficacy characteristics of the entire study population, neratinib + capecita Bin can benefit them significantly, and no new safety issues have been seen
.
For patients with HER2+ mBC who are only treated with trastuzumab, neratinib may provide additional benefits
.
Nelatinib + capecitabine can significantly benefit them, and no new ones have been seen.
Security issues
.
Original source:
Ming Shen Dai, et al.
Analysis of the pan‑Asian subgroup of patients in the NALA Trial:a randomized phase III NALA Trial comparing neratinib+capecitabine(N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+ metastatic breast cancer (mBC) previously treated with two or more HER2‑directed regimens.
Breast Cancer Research and Treatment
https://doi.
org/10.
1007/s10549-021-06313-5
Leave a message here
